XPJ(中国)有限公司官网

Cure Genetics Completed $60 Million Series B Finan...
2022.01.05
Cure Genetics Completed $60 Million Series B Finan...
On January 5, 2022, Cure Genetics Biotechnology Co., Ltd. (hereinafter referred to as "CureGenetics") announced the completion of a US$60 million Series B financing. This round of financing was led by strategic investor Advantech Capital, followed by Oriza Holdings, BOCG and Qiming Venture Partners, with China Renaissance acting as the exclusive financial advisor.

More

>
Boehringer Ingelheim and Cure Genetics Collaborate...
2021.01.18
Boehringer Ingelheim and Cure Genetics Collaborate...
Boehringer Ingelheim (BI) and Cure Genetics Co., Ltd (Cure Genetics) today announced a collaboration to develop novel adeno-associated viral (AAV) vectors for next-generation gene therapy through Cure Genetics's proprietary VELPTM platform. This new collaboration combines BI's experience in disease mechanism research and gene therapy development with Cure Genetics's expertise in viral library construction and high-efficient in vivo AAV screening, providing patients with potentially safer and more efficient novel AAV serotypes.

More

>
Cure Genetics Ranked among 2020 China’s Top 80 Hea...
2020.10.20
Cure Genetics Ranked among 2020 China’s Top 80 Hea...
On October 17, Cure Genetics was listed among the VentureBond 2020 China's Top 80 Healthcare Innovation Companies.

More

>
Cure Genetics’ two projects were selected for the ...
2019.12.13
Cure Genetics’ two projects were selected for the ...
Recently, the candidate projects for the 2019 Gusu Innovation and Entrepreneurship Leading Talents Program were announced, and two projects from Cure Genetics were selected, namely the development of novel adeno-associated viral vectors with tissue-specific targeting and the application of innovative AAV serotype for genetic disease treatment.

More

>
友情链接: